Hydroxychloroquine shows promise for reducing some of the debilitating systems associated with primary progressive multiple sclerosis, a new study reports.
Researchers from Yale University have discovered tow cytokines that could help explain how some people develop PPMS. They report a simple genetic test could be used to identify those most at risk of developing progressive multiple sclerosis.
According to researchers, a small preliminary study could show promise for a new treatment for those with primary progressive multiple sclerosis.
FDA approves a new drug to treat both relapsing-remitting multiple sclerosis and primary progressive MS.
Clinical trials are showing positive results for the treatment of both relapsing multiple sclerosis and primary progressive MS.